Peficitinib治疗传统DMARDs应答不足类风湿关节炎的III期RAJ3试验
RAJ3是一项随机双盲安慰剂对照III期研究,共507例对既往DMARDs应答不足的RA患者接受peficitinib 100 mg每日一次、150 mg每日一次、安慰剂或开放标签依那西普治疗52周。主要终点第12周/提前终止时ACR20应答率在100 mg组57.7%、150 mg组74.5%,均显著高于安慰剂组30.7%(p<0.001),两剂量组耐受性总体良好。
要点
- 第12周/ET时ACR20应答率peficitinib 100 mg组57.7%、150 mg组74.5%,均显著优于安慰剂30.7%。
- ACR50/70应答率及DAS28-CRP/ESR、ACR核心指标改善在两剂量组均显著优于安慰剂(p<0.001)。
- 严重感染和带状疱疹相关疾病发生率peficitinib组高于安慰剂,但未见明确剂量依赖性增加。
核心结论
- 在对传统DMARDs应答不足的RA患者中,peficitinib 100 mg或150 mg每日一次可有效减轻RA症状,与安慰剂相比耐受性良好。
研究设计与样本
- 随机、双盲、安慰剂对照III期研究(RAJ3,NCT02308163),507例接受治疗;分组为peficitinib 100 mg每日一次、150 mg每日一次、安慰剂或开放标签依那西普,疗程52周,安慰剂组第12周起转换为peficitinib 100或150 mg每日一次。
主要发现
- 第12周/提前终止时ACR20应答率:peficitinib 100 mg组57.7%、150 mg组74.5%,安慰剂组30.7%(p<0.001)。
- 两剂量组ACR50/70应答率均高于安慰剂,ACR应答改善维持至第52周。
- 第12周/ET时两剂量组DAS28-CRP/ESR及ACR核心指标较基线的改善均显著大于安慰剂(p<0.001)。
- 不良事件发生率在各治疗组间相似;严重感染和带状疱疹相关疾病发生率peficitinib组高于安慰剂,但无明确剂量依赖性增加。
关键数值与推荐
- 主要终点为第12周/提前终止时的ACR20应答。
- ACR20应答率:peficitinib 100 mg 57.7%、150 mg 74.5% vs 安慰剂30.7%,p<0.001。
- DAS28-CRP/ESR及ACR核心指标改善在两剂量组均显著优于安慰剂,p<0.001。
临床怎么用
- 对传统DMARDs应答不足的RA患者,可考虑每日一次peficitinib 100 mg或150 mg治疗。
- 用药期间需关注严重感染与带状疱疹相关疾病风险。
局限性
- 原文摘要未报告研究局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To investigate the efficacy and safety of peficitinib, an oral Janus kinase inhibitor, in patients with rheumatoid arthritis (RA). METHODS: In this double-blind phase III study, patients with RA and an inadequate response to prior disease-modifying anti-rheumatic drugs (DMARDs) were randomised to peficitinib 100 mg once daily, peficitinib 150 mg once daily, placebo or open-label etanercept for 52 weeks' treatment; placebo-treated patients were switched at week 12 to peficitinib 100 or 150 mg once daily. The primary endpoint was American College of Rheumatology (ACR)20 response at week 12/early termination (ET). Secondary endpoints (assessed throughout) included ACR20, ACR50 and ACR70 response, changes from baseline in disease activity scores (DAS)28 and ACR core parameters, adverse events (AEs) and changes in clinical or laboratory measurements. RESULTS: In total, 507 patients received treatment. ACR20 response rates at week 12/ET were significantly higher in the peficitinib 100 mg (57.7%) and 150 mg (74.5%) groups versus placebo (30.7%) (p<0.001). ACR50/70 response rates were also higher for both peficitinib doses versus placebo. Improvements in ACR response were maintained until week 52. Changes from baseline in DAS28-C-reactive protein/erythrocyte sedimentation rate and the ACR core set were significantly greater for both peficitinib doses versus placebo at week 12/ET (p<0.001). AE incidence was similar across treatment arms. Incidence of serious infection and herpes zoster-related disease was higher with peficitinib versus placebo, but with no clear dose-dependent increase. CONCLUSIONS: In patients with RA and inadequate response to DMARDs, peficitinib 100 mg once daily or 150 mg once daily was efficacious in reducing RA symptoms and was well tolerated compared with placebo. TRIAL REGISTRATION NUMBER: NCT02308163.
引用
- Tanaka Y, Takeuchi T, Tanaka S, et al. Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to conventional DMARDs: a randomised, double-blind, placebo-controlled phase III trial (RAJ3). Ann Rheum Dis. 2019. PMID: 31350270. doi:10.1136/annrheumdis-2019-215163
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。